Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Keisuke Yamakita"'
Autor:
Toru Nakamura, Tsuyoshi Hayashi, Yasutoshi Kimura, Hiroshi Kawakami, Kuniyuki Takahashi, Hirotoshi Ishiwatari, Takuma Goto, Masayo Motoya, Keisuke Yamakita, Yusuke Sakuhara, Michihiro Ono, Eiichi Tanaka, Makoto Omi, Katsuhiko Murakawa, Tomoya Iida, Tamaki Sakurai, Shin Haba, Takehiro Abiko, Yoichi M. Ito, Hiroyuki Maguchi, Satoshi Hirano, Hokkaido Pancreatic Cancer Study Group (HOPS)
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract Although neoadjuvant therapy (Nac) is recommended for high-risk resectable pancreatic cancer (R-PDAC), evidence regarding specific regimes is scarce. This report aimed to investigate the efficacy of S-1 Nac for R-PDAC. In a multicenter phase
Externí odkaz:
https://doaj.org/article/89410a9d2cbf4f059c43f426b88a7f31
Autor:
Yukiyasu Okamura, Narikazu Boku, Paula Ghaneh, William Greenhalf, Satoru Yasukawa, Hiroto Narimatsu, Akira Fukutomi, Masaru Konishi, Soichiro Morinaga, Hirochika Toyama, Atsuyuki Maeda, Yasuhiro Shimizu, Shoji Nakamori, Naohiro Sata, Keisuke Yamakita, Amane Takahashi, Wataru Takayama, Ryuzo Yamaguchi, Moriaki Tomikawa, Akio Yanagisawa, John P. Neoptolemos, Katsuhiko Uesaka
Publikováno v:
Cancer Reports, Vol 5, Iss 5, Pp n/a-n/a (2022)
Abstract Background Expression of human equilibrative nucleoside transporter‐1 (hENT1) is reported to predict survival of gemcitabine (GEM)‐treated patients. However, predictive values of immunohistochemical hENT1 expression may differ according
Externí odkaz:
https://doaj.org/article/15f7769b1eba4cfe9498e1cdf62cb898
Autor:
Masaki Kuwatani, Toru Nakamura, Tsuyoshi Hayashi, Yasutoshi Kimura, Michihiro Ono, Masayo Motoya, Koji Imai, Keisuke Yamakita, Takuma Goto, Kuniyuki Takahashi, Hiroyuki Maguchi, Satoshi Hirano, Hokkaido Pancreatic Cancer Study Group (HOPS)
Publikováno v:
Gut and Liver, Vol 14, Iss 2, Pp 269-273 (2020)
Neoadjuvant chemotherapy/neoadjuvant chemoradiotherapy (NAC/NACRT) can be performed in patients with pancreatic cancer to improve survival. We aimed to clarify the clinical outcomes of biliary drainage with a metal stent (MS) or a plastic stent (PS)
Externí odkaz:
https://doaj.org/article/e9a1f2fb138a4e03b54c855761595901
Autor:
Yasutoshi Kimura, Toru Nakamura, Tsuyoshi Hayashi, Masaki Kuwatani, Masayo Motoya, Makoto Yoshida, Masafumi Imamura, Minoru Nagayama, Hiroshi Yamaguchi, Keisuke Yamakita, Takuma Goto, Yusuke Sakuhara, Kuniyuki Takahashi, Hiroyuki Maguchi, Satoshi Hirano, Ichiro Takemasa
Publikováno v:
Annals of Gastroenterological Surgery, Vol 3, Iss 5, Pp 523-533 (2019)
Abstract Background and Aim Effective multidisciplinary approaches for unresectable pancreatic cancer (UR‐PC) that include modern chemotherapeutic regimens and subsequent conversion surgery (CS) are being developed. The aim of this study was to eva
Externí odkaz:
https://doaj.org/article/22208a636cd54d64861323ddb6ea2be9
Autor:
Kenji Takahashi, Kazuya Koyama, Yu Ota, Hidetaka Iwamoto, Keisuke Yamakita, Satoshi Fujii, Yohei Kitano
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Although non-coding RNAs (ncRNAs) are involved in disease pathogenesis, their contributions to pancreatic ductal adenocarcinoma (PDAC) remain unclear. Recently, the interrelationship between two classes of ncRNA, long non-coding RNAs (lncRNAs), and m
Externí odkaz:
https://doaj.org/article/d484b448699b4077b4e166afedd1a030
Autor:
Masahiko Tanigawa, Yutaka Koga, Yoshiki Naito, Hiroshi Yamaguchi, Takeshi Iwasaki, Kenichi Kohashi, Nobuyuki Ohike, Keiji Hanada, Michiyo Higashi, Masato Komatsu, Hiroshi Imai, Keisuke Yamakita, Tatsuya Nagakawa, Yoshinobu Okabe, Seiya Kato, Hirotsugu Noguchi, Toshiyuki Nakayama, Masanori Yasuda, Hironori Kusano, Jun Akiba, Yoshinao Oda, Hirohisa Yano
Publikováno v:
HistopathologyReferences. 81(3)
Hamartomas in the pancreas are rare and are often histologically and morphologically similar to solitary fibrous tumours (SFTs). We examined the differences between hamartomas and SFTs at the molecular level. METHODS AND RESULTS: Thirteen patients hi
Autor:
Toru Nakamura, Tsuyoshi Hayashi, Yasutoshi Kimura, Hiroshi Kawakami, Kuniyuki Takahashi, Hirotoshi Ishiwatari, Takuma Goto, Masayo Motoya, Keisuke Yamakita, Yusuke Sakuhara, Michihiro Ono, Eiichi Tanaka, Makoto Omi, Katsuhiko Murakawa, Tomoya Iida, Tamaki Sakurai, Shin Haba, Takehiro Abiko, Yoichi ITO, Hiroyuki Maguchi, Satoshi Hirano
Background Although neoadjuvant therapy (Nac) is recommended for high-risk resectable pancreatic cancer (R-PDAC), evidence regarding specific regimes is scarce. This report aimed to investigate the efficacy of S-1 Nac for R-PDAC. Methods In a multice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e6f7ff34cca86e58fce6955c5912fcd5
https://doi.org/10.21203/rs.3.rs-1147465/v1
https://doi.org/10.21203/rs.3.rs-1147465/v1
Autor:
Masakazu Haneda, Takayuki Kogure, Yuko Suzuki, Keisuke Yamakita, Hidetaka Iwamoto, Satoshi Fujii, Tushar Patel, Kenji Takahashi, Tsuguhito Ota, Yohei Kitano, Yu Ota
Publikováno v:
Cancer Science
The role of long noncoding RNAs (lncRNAs) in the epithelial‐mesenchymal transition (EMT) in pancreatic ductal adenocarcinoma (PDAC) is unclear. Some lncRNAs can be transferred by extracellular vesicles (EVs) and have potential as biomarkers. Here,
Autor:
Toru, Nakamura, Tsuyoshi, Hayashi, Yasutoshi, Kimura, Hiroshi, Kawakami, Kuniyuki, Takahashi, Hirotoshi, Ishiwatari, Takuma, Goto, Masayo, Motoya, Keisuke, Yamakita, Yusuke, Sakuhara, Michihiro, Ono, Eiichi, Tanaka, Makoto, Omi, Katsuhiko, Murakawa, Tomoya, Iida, Tamaki, Sakurai, Shin, Haba, Takehiro, Abiko, Yoichi M, Ito, Hiroyuki, Maguchi, Satoshi, Hirano, Akinobu, Taketomi
Publikováno v:
Scientific reports. 12(1)
Although neoadjuvant therapy (Nac) is recommended for high-risk resectable pancreatic cancer (R-PDAC), evidence regarding specific regimes is scarce. This report aimed to investigate the efficacy of S-1 Nac for R-PDAC. In a multicenter phase II trial
Autor:
Yasuhiro Shimizu, Hiroto Narimatsu, Akira Fukutomi, Hirochika Toyama, Wataru Takayama, Satoru Yasukawa, Naohiro Sata, Paula Ghaneh, Narikazu Boku, Ryuzo Yamaguchi, Katsuhiko Uesaka, Moriaki Tomikawa, Akio Yanagisawa, Shoji Nakamori, William Greenhalf, Yukiyasu Okamura, Keisuke Yamakita, Soichiro Morinaga, Amane Takahashi, Atsuyuki Maeda, John P. Neoptolemos, Masaru Konishi
Publikováno v:
Cancer Reports. 5
BACKGROUND Expression of human equilibrative nucleoside transporter-1 (hENT1) is reported to predict survival of gemcitabine (GEM)-treated patients. However, predictive values of immunohistochemical hENT1 expression may differ according to the antibo